Jane Street
ELVN icon

Jane Street’s Enliven Therapeutics ELVN Stock Holding History

Jane Street’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-163,519
Closed -$6.94M – 11915
2026
Q1 		$6.41M Buy
163,519
+61,548
+60% +$1.71M ﹤0.01% 3137
2025
Q4 		$1.57M Buy
+101,971
New +$2.03M ﹤0.01% 5259
2025
Q3 		– Sell
-56,981
Closed -$1.14M – 10978
2025
Q2 		$1.14M Buy
56,981
+27,630
+94% +$523K ﹤0.01% 5363
2025
Q1 		$578K Buy
+29,351
New +$632K ﹤0.01% 6596
2024
Q4 		– Sell
-30,793
Closed -$786K – 9669
2024
Q3 		$786K Sell
30,793
-22,212
-42% -$514K ﹤0.01% 6351
2024
Q2 		$1.24M Buy
53,005
+42,603
+410% +$897K ﹤0.01% 5370
2024
Q1 		$183K Sell
10,402
-5,282
-34% -$81K ﹤0.01% 8238
2023
Q4 		$217K Buy
+15,684
New +$192K ﹤0.01% 8096
2023
Q3 		– Sell
-10,531
Closed -$215K – 8804
2023
Q2 		$215K Sell
10,531
-7,913
-43% -$160K ﹤0.01% 7600
2023
Q1 		$404K Buy
+18,444
New +$375K ﹤0.01% 6693
2020
Q3 		– Sell
-2,835
Closed -$314K – 7297
2020
Q2 		$314K Buy
+2,835
New +$317K ﹤0.01% 5764

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Jane Street's ELVN Position: Q2 2026 in Review

Jane Street sold out of Enliven Therapeutics (ELVN) in Q2 2026, closing a stake of 163,519 shares — an estimated $6.94M sold.

Jane Street first reported a position in ELVN in Q2 2020 and held it in 11 quarters. The position peaked at $6.41M in Q1 2026. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Jane Street reported no remaining Enliven Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 163,519 Enliven Therapeutics shares in Q2 2026, an estimated $6.94M.
  • Jane Street first reported a position in Enliven Therapeutics in Q2 2020 and held it in 11 quarters.
  • Jane Street's Enliven Therapeutics position peaked at $6.41M in Q1 2026.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.